Oral Muvalaplin effectively lowers lipoprotein (a) with no serious adverse effects, shows Initial phase 1 trial
Australia: Daily administration of Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, for 14 days lowered Lipoprotein(a) levels up to 65% and was not associated with tolerability...
South Australia Stephenj Nicholls Monash University Oral Small Molecule Inhibitor Randomized Clinical Journal Of The American Medical Association
Source: medicaldialogues.in